[1] |
LYNCH T J,BELL D W,SORDELLA R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med,2004,350(21):2129-2139.
|
[2] |
PAEZ J G,JÄNNE P A,LEE J C,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science,2004,304(5676):1497-1500.
|
[3] |
MOK T S,WU Y L,THONGPRASERT S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009,361(10):947-957.
|
[4] |
中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组. 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识[J]. 中华病理学杂志,2011,40(10):700-702.
|
[5] |
NOTOMI T,OKAYAMA H,MASUBUCHI H,et al.Loop-mediated isothermal amplification of DNA[J]. Nucleic Acids Res,2000,28(12):E63.
|
[6] |
SUGIHARA T,KODA M,MAEDA Y,et al.Rapid identification of bacterial species with bacterial DNA microarray in cirrhotic patients with spontaneous bacterial peritonitis[J]. Intern Med,2009,48(1):3-10.
|
[7] |
MOK T S,WU Y L,THONGPRASERT S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009,361(10):947-957.
|
[8] |
MITSUDOMI T,MORITA S,YATABE Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label, randomised phase 3 trial[J]. Lancet Oncol,20l0,1l(2):12l-128.
|
[9] |
MAEMONDO M,INOUE A,KOBAYASHI K,et al.Cefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR[J]. N Engl J Med,2010,362(25):2380-2388.
|
[10] |
非小细胞肺癌血液EGFR基因突变检测中国专家组. 非小细胞肺癌血液EGFR基因突变检测中国专家共识[J]. 中华医学杂志,20l5,95(46):3721-3726.
|
[11] |
DOUILLARD J Y,OSTOROS G,COBO M,et al.First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients:a phase-Ⅳ,open-label,single-arm study[J]. Br J Cancer,2014,110(1):55-62.
|